Search Results - "Mele, Mireia"

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial by Ciruelos, Eva, Villagrasa, Patricia, Pascual, Tomás, Oliveira, Mafalda, Pernas, Sonia, Paré, Laia, Escrivá-de-Romaní, Santiago, Manso, Luis, Adamo, Barbara, Martínez, Eduardo, Cortés, Javier, Vazquez, Silvia, Perelló, Antonia, Garau, Isabel, Melé, Mireia, Martínez, Noelia, Montaño, Alvaro, Bermejo, Begoña, Morales, Serafin, Echarri, María J, Vega, Estela, González-Farré, Blanca, Martínez, Débora, Galván, Patricia, Canes, Jordi, Nuciforo, Paolo, Gonzalez, Xavier, Prat, Aleix

“…To assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced breast cancer. PATRICIA is a…”
Get full text

Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients by Rodríguez-Balada, Marta, Roig, Bàrbara, Melé, Mireia, Albacar, Cinta, Serrano, Sara, Salvat, Mònica, Querol, Montserrat, Borràs, Joan, Martorell, Lourdes, Gumà, Josep

“…•An 8% of diagnostic yield was obtained in the analysis of a 25 genes-panel.•Multigene panel should be included as a diagnostic tool in genetic testing.•PALB2…”
Get full text

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study by Gil-Gil, Miguel J., Bellet, Meritxell, Bergamino, Milana, Morales, Serafín, Barnadas, Agustí, Manso, Luís, Saura, Cristina, Fernández-Ortega, Adela, Garcia-Martinez, Elena, Martinez-Jañez, Noelia, Melé, Mireia, Villagrasa, Patricia, Celiz, Pamela, Perez Martin, X., Ciruelos, Eva, Pernas, Sonia

“…BACKGROUNDThe CAPRICE trial was designed to specifically evaluate neoadjuvant pegylated liposomal doxorubicin (PLD) in elderly patients or in those with other…”
Get full text

In silico , in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample by Rodríguez-Balada, Marta, Roig, Bàrbara, Martorell, Lourdes, Melé, Mireia, Salvat, Mònica, Vilella, Elisabet, Borràs, Joan, Gumà, Josep

“…Abstract Ascertaining the clinical consequences of BRCA1 and BRCA2 variants of uncertain significance (VUS) is currently indispensable for providing effective…”
Get full text

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial by Loibl, Sibylle, Marmé, Frederik, Martin, Miguel, Untch, Michael, Bonnefoi, Hervé, Kim, Sung-Bae, Bear, Harry, McCarthy, Nicole, Melé Olivé, Mireia, Gelmon, Karen, García-Sáenz, José, Kelly, Catherine M, Reimer, Toralf, Toi, Masakazu, Rugo, Hope S, Denkert, Carsten, Gnant, Michael, Makris, Andreas, Koehler, Maria, Huang-Bartelett, Cynthia, Lechuga Frean, Maria Jose, Colleoni, Marco, Werutsky, Gustavo, Seiler, Sabine, Burchardi, Nicole, Nekljudova, Valentina, von Minckwitz, Gunter

“…About one third of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have residual invasive disease…”
Get full text

Design and development of a new pictorial tool to facilitate communication around advance care planning by Baylina Melé, Mireia, Villavicencio-Chávez, Christian, Garzón Rodríguez, Cristina, Edo-Gual, Montserrat, Crespo, Iris

“…Abstract Background Advance care planning (ACP) aims to ensure that people with chronic or advanced disease receive medical care that is consistent with their…”
Get full text

Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast) by De La Haba, Juan, Anton, Antonio, Quiroga, Vanesa, Guerrero, Angel, Andrés, Raquel, Mele, Mireia, Gonzalez- Santiago, Santiago, Perez-Fidalgo, Jose Alejandro, Ramon y Cajal, Teresa, Escudero, Maria Jose, Bezares, Susana, Caballero, Rosalia, Rojo, Federico

“…1093 Background: Epigenetic silencing by aberrant BRCA1/2 promoters’ methylation ( BRCA-meth) can be responsible for a dysfunctional BRCA protein. BRCA-meth…”
Get full text

Deterioro cognitivo inducido por los tratamientos oncológicos sistémicos en el cáncer de mama no metastático: revisión de estudios by Agustina Sirgo, Beatriz Rubio, Eva Forcadell, Mireia Mele, Josep Guma

“…Las mujeres con cáncer de mama se quejan de problemas cognitivos tras los tratamientos oncológicos sistémicos. Esto conduce a estudiar el efecto de estos…”
Get full text

Fatal pneumonitis induced by oxaliplatin by Arévalo Lobera, Sara, Sagastibeltza Mariñelarena, Naiara, Elejoste Echeberría, Ibone, Melé Olivé, Mireia, Egaña Otaño, Larraitz, Basterretxea Badiola, Laura, La Casta Muñoa, Adelaida, Azkue Gabilondo, Mikel

“…Oxaliplatin has been approved for adjuvant treatment of colorectal cancer. Toxicity induced by oxaliplatin is moderate and manageable, but some isolated cases…”
Get full text

A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA 2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study) by De La Haba, Juan, Guerrero-Zotano, Angel, Perez-Fidalgo, Jose Alejandro, Gonzalez Santiago, Santiago, Muñoz, Montserrat, Andres, Raquel, Cruz Zambrano, Cristina, Moran Salama, Sebastian, Lopez-Tarruella, Sara, Quiroga Garcia, Vanesa, Servitja, Sonia, Mele, Mireia, Alonso Soler, Sonia, Adamo, Barbara, Escudero, Maria Jose, Martin, Nuria, Bezares, Susana, Caballero, Rosalia, Esteller, Manel, Rojo, Federico

“…Abstract only…”
Get full text

3003: Changes in oxidative stress and the inflammatory system in breast cancer patients by Avila, Victor D Calderón, Franco, Andrea Jiménez, Capdevila, Marta Canela, Pablo, Raquel García, Aguilar, Juan M Jiménez, Castañé, Helena, Mora, Pablo Araguas, Chacón, Bárbara A Malavé, Benitez, Gemma, Acosta, Johana C., Benavides, Rocio, Troncho, Cecilia Escuin, Engel, Olga, Parada, David, De la flor, Miriam, Jordà, Coia, Melé, Mireia, Repkova, Jana, Prat, Meritxell Arenas

Get full text

2837: Metabolic profiling of plasma and tissue in breast cancer patients: uncovering therapeutic response by Jiménez-Franco, Andrea, Calderón, David, Jiménez-Aguilar, Juanma, Canela-Capdevila, Marta, García-Pablo, Raquel, Castañé, Helena, Araguas, Pablo, Malave, Bárbara, Acosta, Johana Cristina, Benavides, Rocío, Árquez, Miguel, Castaño, Fredy, Riu, Francesc, de la Flor, Miriam, Jordà, Coia, Melé, Mireia, Repkova, Jana, Amillano, Kepa, Camps, Jordi, Joven, Jorge, Arenas, Meritxell

Get full text

Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study by Ciruelos, Eva, Pascual, Tomás, Oliveira, Mafalda, Escrivá-de-Romaní, Santiago, Pernas, Sonia, Paré, Laia, Adamo, Barbara, Martínez, Eduardo, Cortés, Javier, Perelló, Antonia, Galan, Maria, Melé, Mireia, Tolosa, Pablo, González-Farré, Blanca, Galván, Patricia, Canes, Jordi, Nuciforo, Paolo, Gonzalez, Xavier, Villagrasa, Patricia, Prat, Aleix

“…Background: CDK4/6 inhibition combined with anti-HER2 therapy is currently being explored in HER2-positive (HER2+) breast cancer (BC). Here, we report the…”
Get full text

Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B by Loibl, Sibylle, Marmé, Frederik, Martin, Miguel, Untch, Michael, Bonnefoi, Hervé, Kim, Sung-Bae, Bear, Harry, Carthy, Nicole Mc, Olivé, Mireia Melé, Gelmon, Karen, Sáenz, José García, Kelly, Catherine M, Reimer, Toralf, Toi, Masakazu, Rugo, Hope S, Seiler, Sabine, Nekljudova, Valentina, Denkert, Carsten, Gnant, Michael, Makris, Andreas, Burchardi, Nicole, von Minckwitz, Gunter

“…Background: About one third of patients with hormone-receptor-positive (HR+), HER2- primary breast cancer with residual invasive disease after neoadjuvant…”
Get full text

Abstract OT2-02-06: Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial by Ciruelos, Eva, Villagrasa, Patricia, Oliveira, Mafalda, Pernas, Sonia, Cortes, Javier, Vazquez, Silvia, Martínez, Noelia, Perello, Antonia, Bermejo, Begoña, Martínez, Eduardo, Garau, Isabel, Melé, Mireia, Montaño, Alvaro, Vega, Estela, Cantos, Blanca, Echarri, María Jose, Pascual, Tomás, Canes, Jordi, Céliz, Pamela, González, Xavier, Prat, Aleix

“…Background: Efficacy Interim results from PATRICIA phase II trial in HER2+/HR+ advanced breast cancer (BC) showed that PAM50 luminal disease was associated…”
Get full text

DETERIORO COGNITIVO INDUCIDO POR LOS TRATAMIENTOS ONCOLÓGICOS SISTÉMICOS EN EL CÁNCER DE MAMA NO METASTÁTICO: REVISIÓN DE ESTUDIOS by Rubio, Beatriz, Sirgo, Agustina, cadell, Eva, Mele, Mireia, Guma, Josep

“…Breast cancer women complain of cognitive problems after systemic oncological treatments. This has lead to study the effect of these treatments on the…”
Get full text

Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer by Ciruelos, Eva, Pascual, Tomás, Villacampa, Guillermo, Pernas, Sonia, Sanchez-Bayona, Rodrigo, Ponce-Lorenzo, Jose Juan, Cantos Sanchez de Ibarguren, Blanca, Escrivá-de-Romaní, Santiago, Perello, Antonia, Montaño, Alvaro, Martinez, Eduardo, López González, Ana, Melé Olivé, Mireia, De La Haba, Juan, Cortes, Javier, Oliveira, Mafalda, Villanueva, Lorea, Gonzalez, Xavier, Villagrasa, Patricia, Prat, Aleix

“…1008 Background: The PATRICIA trial (cohorts A-B) demonstrated that palbociclib plus trastuzumab (T) is safe and active in patients (pts) with T-pretreated…”
Get full text

Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial by Turner, Nicholas C., Marmé, Frederik, Kim, Sung-Bae, Bonnefoi, Herve R., García-Sáenz, José A., Torres, Antonio A., Bear, Harry Douglas, Tesch, Hans, Melé Olivé, Mireia, Mc Carthy, Nicole, Cruz Jurado, Josefina, Im, Seock-Ah, Liu, Yuan, Zhang, Zhe, Weber, Karsten Ernst, Felder, Bärbel, Nekljudova, Valentina, Reimer, Toralf, Denkert, Carsten, Loibl, Sibylle

“…502 Background: The PENELOPE-B phase III trial investigated the addition of one year of palbociclib to endocrine therapy (ET), in patients with hormone…”
Get full text